HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy

BACKGROUND: HER2 (or ERBB2) amplification is an important mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKI). The benefits of HER2-targeted therapy have been limited. Herein, we investigated the molecular and clinical patterns of HER2 amplification in non-small cell lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Jiadi, Huang, Yihua, Liao, Jun, Pang, Lanlan, Fang, Wenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609241/
https://www.ncbi.nlm.nih.gov/pubmed/34824536
http://dx.doi.org/10.2147/OTT.S335217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609241/
https://www.ncbi.nlm.nih.gov/pubmed/34824536
http://dx.doi.org/10.2147/OTT.S335217

Ejemplares similares